Should CHO K1 Media Launch Require Action From Thermo Fisher Scientific Stock Investors?

Simply Wall St.10-01

Thermo Fisher Scientific recently launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin free basal and feed media in liquid and dry powder formats intended ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2672518730?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/97023-card/1788974855778","is_english":true,"pubTime":"2026-10-01 13:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2672518730","market":"us","top_or_hot":-1,"title":"Should CHO K1 Media Launch Require Action From Thermo Fisher Scientific Stock Investors?","media":"Simply Wall St.","content":"<div>\n<p>Thermo Fisher Scientific recently launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin free basal and feed media in liquid and dry powder formats intended ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/should-cho-k1-media-launch-require-action-from-thermo-fisher\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should CHO K1 Media Launch Require Action From Thermo Fisher Scientific Stock Investors?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould CHO K1 Media Launch Require Action From Thermo Fisher Scientific Stock Investors?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-01 13:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/should-cho-k1-media-launch-require-action-from-thermo-fisher><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thermo Fisher Scientific recently launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin free basal and feed media in liquid and dry powder formats intended ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/should-cho-k1-media-launch-require-action-from-thermo-fisher\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GNMX","symbol_name":"Corgi Genomics & Precision Medicine ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/should-cho-k1-media-launch-require-action-from-thermo-fisher","article_id":"2672518730","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/97023-card/1788974855778"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/should-cho-k1-media-launch-require-action-from-thermo-fisher","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2672518730","pubTimestamp":1790831756,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Thermo Fisher Scientific recently launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin free basal and feed media in liquid and dry powder formats intended to support CHO-K1 cell growth, protein production, and smoother progression from process development through manufacturing.\nThe product targets biologics and biosimilars developers that rely on CHO-K1 cell lines and offers multiple ready to use media and feed combinations that can shorten...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GNMX":"Corgi Genomics & Precision Medicine ETF","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0061474960.USD":"天利环球焦点基金AU Acc","BK4585":"ETF&股票定投概念","LU0528227936.USD":"富达环球人口趋势基金A-ACC","BK4534":"瑞士信贷持仓","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1548497426.USD":"安联环球人工智能AT Acc","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","HRTS":"Tema Heart & Health ETF","LU0096362180.USD":"CT (LUX) I GLOBAL FOCUS \"DU\" (USD)","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2125909759.SGD":"Natixis Thematics Safety H-R/A SGD","BK4535":"淡马锡持仓","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","FMED":"Fidelity Disruptive Medicine ETF","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","ISBC":"投资者银行","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","BK4588":"碎股","LU1923622291.USD":"Natixis Thematics Safety R/A USD","TMED":"T. Rowe Price Health Care ETF","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1633808545.USD":"ALLIANZ GLOBAL EQUITY GROWTH \"AT\" (USD) ACC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","TMO":"赛默飞世尔","LU2063271972.USD":"富兰克林创新领域基金","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4211":"区域性银行","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU0251142724.SGD":"Fidelity America A-SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"CHO K1 媒体发布会是否需要赛默飞世尔科学股票投资者采取行动？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNMX":0.6,"TMED":0.6,"HRTS":0.6,"ISBC":1.5,"TMO":1.5,"FMED":0.6},"content_text":"Thermo Fisher Scientific recently launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin free basal and feed media in liquid and dry powder formats intended to support CHO-K1 cell growth, protein production, and smoother progression from process development through manufacturing. The product targets biologics and biosimilars developers that rely on CHO-K1 cell lines and offers multiple ready to use media and feed combinations that can shorten upstream process development while aligning with regulatory expectations for cGMP workflows. We will now look at how Thermo Fisher Scientific's investment narrative could be affected by this cGMP-ready CHO-K1 media portfolio launch.  Scan how Thermo Fisher Scientific fits into the broader bioprocessing theme by comparing it with a curated group of list of solid balance sheet and fundamentals (25 results) supporting long-term life sciences demand. AdvertisementThermo Fisher Scientific Investment Narrative Recap To own Thermo Fisher Scientific, you need to believe that steady demand for pharma and biotech tools, services, and consumables can offset softer academic and government spending, China volatility, and tariff pressure. The nearest operational swing factor is how quickly biopharma capital spending and bioprocessing volumes translate into higher consumables pull through across its portfolio. The new CHO K1 media launch nudges that near term catalyst in a supportive direction because it adds another cGMP ready consumable line tied directly to biologics workflows. The biggest risk does not change much. Prolonged funding uncertainty and policy pressure on instruments, combined with FX and China softness, could still cap margin progress. Among recent updates, the Gibco CHO K1 Catalog Panel looks most relevant for the current story. It fits directly into Thermo Fisher Scientific’s push to build higher margin, recurring consumables around bioproduction, where customers value ready to use, regulatory aligned options that can run from small scale development through full manufacturing. For you as an investor, the key question is execution. If management integrates this CHO K1 media range into broader bioprocessing accounts, it can support more stable consumable streams that matter when instruments face macro headwinds. If adoption is slower or biologics development cycles pause, that catalyst loses some punch while existing risks stay in focus. Thermo Fisher Scientific's narrative projects US$54.8b revenue and US$10.0b earnings by 2029. This assumes 5.8% yearly revenue growth and an earnings increase of US$3.0b from US$7.0b today. Uncover why Thermo Fisher Scientific's fair value indicates a 4% potential downside to its current price, which leaves little room for error. NYSE:TMO 1-Year Stock Price Chart Exploring Other Perspectives One alternate view focuses on geopolitical risk. From that perspective, Thermo Fisher Scientific faces challenges in offsetting trade friction and pricing pressure, with bearish analysts only penciling in about US$54.2b of revenue and US$8.7b of earnings by 2029. Those expectations sit below consensus, and this new CHO K1 media launch could eventually shift that debate. Explore 3 other Thermo Fisher Scientific fair value estimates, including one that suggests up to 8% downside from the current price. Form Your Own Verdict Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Thermo Fisher Scientific. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance.  Looking For More Investment Ideas Beyond Thermo Fisher Scientific? Thermo Fisher Scientific might sit at the center of your watchlist today, but you keep your edge by regularly scanning for other opportunities that match your risk profile and return goals. The Simply Wall St Screener helps you do that quickly by filtering for fundamentals that matter to you.  If you want a focus on quality at a reasonable price, scan a curated set of opportunities through 31 high quality undervalued stocks that combine stronger fundamentals with more modest expectations baked into their prices. For investors who care most about resilience, start with 31 resilient stocks with low risk scores and narrow in on companies that score better on balance sheet strength and risk factors. If income is your priority, use 7 dividend fortresses to zero in on payers offering higher yields that are still backed by underlying business performance.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Thermo Fisher Scientific might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2672518730","isCrawlerRequest":true}